Clinical Trial

Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.
Protocol Amendment History 5 changes
notable Enrollment increased: 90 -> 105 participants 2026-08-13
minor Trial arms changed: 8 -> 10 2026-08-13
notable Primary completion pushed: 2027-02 -> 2027-10 2026-08-13
minor Completion pushed: 2027-02 -> 2027-10 2026-08-13
notable Sponsor changed: RAGE Bio -> Atisama Therapeutics 2026-06-05
Trial Details
NCT Number NCT07285122
Lead Sponsor Atisama Therapeutics
Conditions Healthy, Healthy Smoker, COPD (Chronic Obstructive Pulmonary Disease), COPD
Enrollment 105 participants
Start Date 2026-02-16
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-12